RESUMEN
BACKGROUND: Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease of the follicles in the apocrine glands and is associated with a deficiency in the innate immunity of the skin. It is characterized by the occurrence of nodules, abscesses, fistulas, scars. OBJECTIVE: Although a relationship has already been demonstrated between HS and innate immunity, IGF-1 status in patients with HS is still unknown. The objective of this pilot study was to determine IGF-1 status in patients with HS as well as its potential relationship with the clinical profile of the disease. METHODS: This monocentric and cross-sectional study involved 39 patients hospitalized at the Dermatology Department of CHU Nantes between November 2014 and January 2018. Clinical data and IGF1 status were collected during the follow-up consultation. RESULTS: Forty-nine percent of the patients had very low levels of IGF-1. At the clinical level, these patients were young and with a short duration of disease. The major difference was that IGF1-deficient patients had a higher BMI than others. The others factors differing between the two patient groups did not reach statistical significance. CONCLUSION: This exploratory pilot study indicates that HS with a low level of IGF-1 could represent a specific phenotype of patients with HS. These preliminary results have to be confirmed with a larger cohort, as they could have practical consequences in the therapeutic care of these patients.
Asunto(s)
Hidradenitis Supurativa , Humanos , Hidradenitis Supurativa/tratamiento farmacológico , Proyectos Piloto , Factor I del Crecimiento Similar a la Insulina/uso terapéutico , Insulina/uso terapéutico , Estudios TransversalesAsunto(s)
Azetidinas/efectos adversos , Síndrome de Hipersensibilidad a Medicamentos/etiología , Melanoma/tratamiento farmacológico , Piperidinas/efectos adversos , Neoplasias Cutáneas/tratamiento farmacológico , Vemurafenib/efectos adversos , Adulto , Anciano , Anciano de 80 o más Años , Azetidinas/uso terapéutico , Síndrome de Hipersensibilidad a Medicamentos/fisiopatología , Quimioterapia Combinada , Femenino , Humanos , Masculino , Melanoma/diagnóstico , Persona de Mediana Edad , Piperidinas/uso terapéutico , Pronóstico , Medición de Riesgo , Muestreo , Índice de Severidad de la Enfermedad , Neoplasias Cutáneas/diagnóstico , Vemurafenib/uso terapéuticoAsunto(s)
Antineoplásicos Inmunológicos/uso terapéutico , Receptor de Muerte Celular Programada 1/antagonistas & inhibidores , Sarcoma/tratamiento farmacológico , Sarcoma/secundario , Neoplasias Cutáneas/tratamiento farmacológico , Neoplasias Cutáneas/patología , Anciano de 80 o más Años , Humanos , Inmunoterapia , Masculino , Inducción de RemisiónRESUMEN
For melanoma patients, surgery is a standard treatment for locoregional skin metastasis (LSM). To assess the frequency and risk factors for positive margins after excision of LSM and their impact on patient overall survival (OS) and progression-free survival (PFS). A monocentric, retrospective observational study was performed including 87 patients with LSM who had undergone surgical excision. Positive margins were found in 45% of patients after excision. After additional excision, 28% of patients still had positive margins. Interestingly, there was no difference in PFS or OS for clear margins after the first or additional excision or for margins that remained positive without additional excision. LSM size was the only identified predictive factor for positive margins. This is the first reported study investigating the frequency of, and risk factors for positive margins of cutaneous LSM, which raises the question of whether additional excision should be performed following positive margin excision.